aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.aTyr Pharma reported a narrowed Q2 2026 net loss of $10.3M, driven by reduced R&D spending on efzofitimod. The company announced a 60% workforce reduction to cut $13M in annual expenses ahead of a planned Phase 3 study for pulmonary sarcoidosis. Although the EFZO-FIT trial missed its primary endpoint, it showed quality-of-life improvements. Additionally, aTyr is advancing preclinical candidate ATYR0101 and expanding its discovery platform.
aTyr Pharma reported second-quarter 2026 results with a reduced net loss versus the year-ago quarter, driven primarily by lower research-and-development spending related to efzofitimod as the company prepares for a planned Phase 3 program.
Financial Highlights
- Net income: Net loss attributable to aTyr Pharma, Inc. of $(10.3M) for 2Q 2026 vs $(19.5M) in 2Q 2025.
- Diluted EPS: Net loss per share, basic and diluted of $(0.11) for 2Q 2026 vs $(0.22) in 2Q 2025.
- Commentary: Reduced R&D spend (primarily lower efzofitimod costs) drove the year‑over‑year improvement in net loss for the quarter.
Business Highlights
- Phase 3 program update: Plans to initiate a new global Phase 3 FVC‑focused study in moderate‑to‑severe pulmonary sarcoidosis following FDA Type C feedback.
- EFZO‑FIT results & impact: The Phase 3 EFZO‑FIT trial missed its steroid‑reduction primary endpoint but showed nominal improvements in KSQ‑Lung, fatigue and quality‑of‑life measures.
- Operational restructuring: Announced a workforce reduction of approximately 60% to conserve cash and reduce roughly $13M of annual operating expenses ahead of the planned Phase 3.
- Pipeline & discovery momentum: Advancing preclinical candidate ATYR0101 (IND‑enabling) and expanding its tRNA synthetase discovery platform for fibrosis and inflammation programs.
Original SEC Filing: aTYR PHARMA INC [ ATYR ] - 10-Q - Aug. 07, 2026